- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00324259
Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer
A Phase II Randomized Study of Physiological (6 mg Daily) and High Dose (30 mg Daily) Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60637
- University of Chicago
-
-
Missouri
-
St. Louis, Missouri, Vereinigte Staaten, 63110
- Washington University School of Medicine
-
-
New York
-
New York, New York, Vereinigte Staaten, 10021
- Memorial Sloan-Kettering Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599
- University of North Carolina Breast Clinic
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Duke University Medical Center
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Case Western University
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Cleveland Clinic, Lerner College of Medicine, Case Western Reserve University
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Postmenopausal women with advanced hormone receptor positive (ER and or PgR) breast cancer, has received prior treatment with an aromatase inhibitor in the advanced disease setting, and experienced at least 24 weeks of progression free survival. As long as the patient experienced an aromatase inhibitor response as defined this way, she is still eligible even if she has received further lines of endocrine therapy, which may include other aromatase inhibitors or tamoxifen, even if these subsequent lines of treatment were unsuccessful (see below for permitted chemotherapy and trastuzumab therapy).
OR
- Postmenopausal women with systemic or unresectable local relapse after taking at least two years of adjuvant aromatase inhibitor therapy.
Clinical diagnosis of postmenopausal status is defined as either:
- Age greater than 50 years and amenorrhea for 1 year
- Bilateral Surgical ovariectomy
- Serum FSH and estradiol level in the postmenopausal range before the initiation of AI therapy.
- If the patient was receiving an LHRH agonist to maintain a postmenopausal state during AI therapy this should be continued since recovery of menses would lead to uncontrolled estrogen exposure and pregnancy during estrogen therapy is contraindicated.
- Tumor cell expression of ER and/or PgR can be ascertained on either the primary or the metastatic site. However when both types of tissue are available, the metastatic site should be used to determine eligibility. ER and/or PgR positive are defined as at least 10% of malignant cells with positive nuclear staining.
- The patients may have received adjuvant and/or neoadjuvant chemotherapy.
- Prior radiotherapy is permitted as long as it was planned before the start of the study medication and is completed within 3 weeks of trial medication starting.
- Prior tamoxifen therapy is also permitted as adjuvant or advanced disease therapy.
- Patients with ER+ HER2+ disease are eligible even of they have received trastuzumab in the past (and even if it was administered in combination with endocrine treatment) as long as they meet all other eligibility criteria. Trastuzumab therapy must be held during estradiol treatment.
- Use of prior experimental agents alone or in combination with endocrine therapy is also permissible, but a wash out of one month is required if the immediate prior therapy involved a study medication that had not been subject to regulatory approval.
- Prior adjuvant chemotherapy is permitted as well as one line of chemotherapy for advanced disease.
- Patient must have at least one measurable lesion defined by RECIST criteria. To be considered measurable, a baseline lesion must have a minimum diameter to compensate for measurement error: 1 cm for soft tissue lesions, 1 cm for lung lesions including pleural lesions measured by CT scan, 1 cm for liver lesions measured by CT scan.
Patients with bone only disease can also be enrolled if they meet the following criteria:
- Four or more lesions more than one cm, measurable on CT scan bone windows.
- At least one tumor marker that is elevated to at least two times the upper limit of normal.
- All patients should have a baseline bone scan with X-ray evaluation of all hot spots, CT chest abdomen and pelvis (with bone windows), and tumor marker assessment. Also CT scan of the extremities should be done on suspicious areas seen on X-ray evaluation of all hot spots if these extremity lesions are to be followed for response.
- The patient must have an ECOG performance status of 0-2
- The patient should have a life expectancy of > 6 months.
- The patient must have adequate hematologic function, defined as ANC >1000/mm3 and platelets > 75,000/mm3.
- The patient must have adequate renal function, defined as serum creatinine less than or equal to 1.5 times the upper limit of normal.
- The patient must have adequate liver function defined as serum bilirubin less than or equal to 1.5 times the upper limit of normal (three times the upper limit of normal for patients with hereditary benign hyperbilirubinaemia), transaminases (ALT, AST) less than or equal to 2.5 times the upper limit of normal in patients without liver metastasis or less than or equal to 5 times the upper limit of normal in patients with liver metastasis.
- For patients with bone metastasis, treatment with i.v. bisphosphonates during the trial is mandatory because of the risk of hypercalcemia. Bisphosphonate therapy must be started before the patient begins protocol therapy.
- Preexisting hypercalcemia should be treated and calcium normalized prior to study entry.
- The patient must give written informed consent prior to initiation of any invasive study-related procedures that would otherwise not be performed, and must be able to comply with scheduled visits and evaluations.
- Inclusion of Women and Minorities: Entry to this study is open to women of all racial and ethnic subgroups.
- Patients with fasting blood glucose level ≤ 200 mg/dL. If greater, hyperglycemia must be treated before initiation of study investigations.
Exclusion Criteria:
- Patients with CNS involvement with metastatic breast cancer or life threatening lymphangitic or large volume lung or liver disease that threatens organ function.
- Patients with history of deep venous thrombosis, pulmonary embolism, stroke, acute myocardial infarction, congestive cardiac failure, untreated hypertension.
- Ischemic changes on a baseline EKG or other evidence of ischemic heart disease.
- Undiagnosed abnormal genital bleeding
- Untreated cholelithiasis
- Fasting serum triglycerides greater than 400. Patients should be treated and triglycerides controlled prior to study entry.
- Treatment with fulvestrant within 12 months of study initiation (fulvestrant has been shown to antagonize estradiol induced apoptosis in preclinical models (5).
- The patient's only qualifying lesion (s) have been previously irradiated or are scheduled for irradiation following study entry.
- Severe or uncontrolled concomitant disease from other causes.
- EGOG Performance status 3 or 4.
- The patient has previous malignancies other than breast cancer except a) adequately treated in situ carcinoma of the cervix, b) localized basal or squamous cell carcinoma of the skin c) any previous malignancy treated with curative intent with a recurrence risk of less than 30%.
- The patient is unable to understand the informed consent or is unlikely to be compliant with the protocol.
- More than one line of palliative chemotherapy for advanced disease.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: Arm 1 (6 mg estradiol)
6 mg of estradiol daily (2 mg tid).
|
|
Aktiver Komparator: Arm 2 (30 mg estradiol)
30 mg of estradiol.
(10 mg tid)
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Clinical Benefit Rate (CR Plus PR Plus SD)
Zeitfenster: 24 weeks after start of treatment
|
Complete response (CR) + partial response (PR) + stable disease (SD) using RECIST 1.0 CR = disappearance of all target lesions PR = at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter SD = neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for progressive disease SD is defined as lack of disease progression by 24 weeks. |
24 weeks after start of treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Progression-free Survival (PFS)
Zeitfenster: Up to 48 weeks
|
Defined as the time from treatment initiation to disease progression or death. Time of last observation for patients remaining in the study and the time at which dose reductions, study drug termination, and withdrawal of consent occurred were treated as censored data. Indicated as number of participants who had not progressed at 12 weeks, 24 weeks, 36 weeks, and 48 weeks. Progression per RECIST 1.0 = at least a 20% increase in the sum of the longest diameter of target lesions taking as references the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions. |
Up to 48 weeks
|
Quality of Life
Zeitfenster: Baseline and Day 28
|
Surveyed using a 6 item estrogen adverse effect questionnaire (headaches, bloating, breast tenderness, retention of fluid, nausea, and vomiting). Used a 5-point scale ranging from 0 (not at all) to 4 (very much). The scores from the 6 estrogen adverse effect items were summed to produce a single score, ranging from 0-24, with higher scores indicating higher adverse effects. |
Baseline and Day 28
|
Quality of Life (FACT-B Mean Score)
Zeitfenster: Day 28
|
Surveyed using the multidimensional Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire The FACT-B (version 4) questionnaire consists of 36 items with five-point scale, ranging from 0-4, where a total score ranges from 0-144 and higher scores indicate better QoL. The total FACT-B score is the sum of scores for five subscales including: physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and specific breast cancer concerns (9 items). |
Day 28
|
Frequency of Response to Re-treatment With the Same Aromatase Inhibitor That Immediately Preceded Treatment With Estradiol on Protocol.
Zeitfenster: 12 weeks post-treatment termination
|
Best overall response
|
12 weeks post-treatment termination
|
Frequency of Response to Re-treatment With Estradiol for Patients Who Have a Secondary Response to an Aromatase Inhibitor After the First Response to Estradiol.
Zeitfenster: Every 3 months
|
Every 3 months
|
|
Overall Survival (OS)
Zeitfenster: Until patient death
|
Until patient death
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Matthew Ellis, M.D., Ph.D., Washington University School of Medicine
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 04-0412 / 201108392
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Neoplasien der Brust
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi Sankyo, Inc.RekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten
-
John MascarenhasNational Cancer Institute (NCI); National Institutes of Health (NIH); Celgene... und andere MitarbeiterAbgeschlossenIDH2-Mutation | Accelerated/Blast-phase Myeloproliferative Neoplasm | Myelofibrose in der chronischen PhaseVereinigte Staaten, Kanada
Klinische Studien zur Östradiol
-
Children's Hospital Medical Center, CincinnatiPatty Brisben Foundation For Women's Sexual HealthAbgeschlossenPrimäre OvarialinsuffizienzVereinigte Staaten
-
Medical College of WisconsinBeendetTransgenderismus | GerinnungsstörungVereinigte Staaten
-
NYU Langone HealthAbgeschlossenFurcht | Angst; Untersuchung, PhobieVereinigte Staaten
-
Affiliated Hospital of Nantong UniversityRekrutierungPrimäre OvarialinsuffizienzChina
-
University Magna GraeciaUnbekanntEndometriose | Chronische BeckenschmerzenItalien
-
TherapeuticsMDAbgeschlossenMenopause | Vulvovaginale Atrophie | Dyspareunie | Schmerzhafter GeschlechtsverkehrVereinigte Staaten
-
Wake Forest University Health SciencesRekrutierungWiederkehrende HarnwegsinfektionVereinigte Staaten
-
Indira IVF Hospital Pvt LtdBeendetUnfruchtbarkeit, weiblich | Gefrorener EmbryotransferIndien
-
BayerAbgeschlossen
-
Lumara Health, Inc.AbgeschlossenHitzewallungenVereinigte Staaten